- Home
- MOMO vs GHRS Comparison
MOMO vs GHRS Comparison
Compare MOMO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOMO | GHRS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOMO | GHRS |
|---|---|---|
| Price | $6.65 | $15.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $13.00 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 711.1K | 174.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $7.98 |
| 52 Week High | $9.22 | $19.51 |
Technical Indicators
Market Signals| Indicator | MOMO | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 50.06 | 49.23 |
| Support Level | $6.41 | $11.84 |
| Resistance Level | $6.73 | $16.24 |
| Average True Range (ATR) | 0.15 | 0.83 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 66.83 | 57.81 |
Price Performance
Historical ComparisonAbout MOMO Hello Group Inc.
Hello Group Inc provides mobile-based social networking services. It enables users to establish and expand social relationships based on location and interests. Its platform includes the Momo mobile application and a variety of related features, functionalities, tools, and services that it provides to users, customers, and platform partners. The company derives its revenue from live video services, value-added services, mobile marketing services, mobile games, and other services. It operates in three segments: Momo's service lines, Tantan's service lines, and QOOL's service lines, out of which Momo's service lines segment derives the majority of revenue.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.